GC203 mushonga mutsva weTIL usina utachiona wakagadzirwa uchishandisa Juncell Therapeutics' proprietary DeepTIL® cell expansion platform uye NovaGMP® gene modification platform. DeepTIL® inoita kuti maTIL ave nesimba zvekuti hapana musanganiswa weIL-2 unodiwa mushure mekuiswa, uye simba rekurapwa ringave rakaderera. NovaGMP® inoshandura maT cells nekushanda kwakafanana neLentiviral vector nenzira ine mari. GC203 yakagadzirwa neinterleukin-7 inozvibatanidza nemembrane-bound interleukin-7, iyo inogona kuchengetedza stemness yememory T cells, kumutsa immune cells dzemukati uye kudzivirira chepfu mumuviri.
Vaongorori vakaedza GC203 pavarwere vakaonekwa vaine kenza yemuchibereko inodzokororwa, pasina kusanganisa IL-2 kana aggressive lymphodepletion. Chinangwa chechidzidzo ichi chaive chekuona kuchengetedzeka uye kushanda kwekurapa uku. Huwandu hwevarwere makumi maviri vakanyoreswa pakati pa09/2021 na01/2024 muongororo ye open-label single-center, umo varwere gumi nevasere vakaongororwa. Varwere vakaongororwa vaive neECOG PS ye1 (55.6%) kana 2 (44.4%) uye vakagamuchira avhareji yekurapa kashanu kwakapfuura (range: 2-11). Varwere 9 (50%) vaive nemaronda matatu kana kupfuura egomarara. Avhareji yeronda raive 57 (range: 13-146) mm.
GC203 yakaratidza mhedzisiro inovimbisa muvarwere vane kenza yemuchibereko inodzokororwa kana kuti yakapararira. Kuchengetedzeka kwacho kwakavandudzika zvakanyanya kana tichienzanisa nekurapa kweTIL kwakajairika, nekuda kwekurapwa kwakaderera uye kubviswa kwemusanganiswa weIL-2. Zvizhinji zveZviitiko Zvakaipa (AEs) zvaive zvegiredhi 1 kana giredhi 2 uye zvaigona kuderedzwa kana kurapwa nezviratidzo. Hapana chiitiko chegiredhi 5 chakaitika. Pakazosvika zuva rekupedzisira ra01/2024, Muongorori-akaongorora Objective Response Rate (ORR) yaive 33.3% (95% CI: 16.3 - 56.3), kusanganisira 11.1% Complete Response (CR). Disease Control Rate (DCR) yaive 83.3% (95% CI, 60.8 - 94.2). Uye chiyero cheOverall Survival (OS) chemwedzi gumi nemiviri chaive 68.8% (95% CI: 49.3 - 95.9). Avhareji yeOS yakanga isati yakura seyakachekwa data.
Muna 2023, Ms. H vakapinzwa muchipatara muna 2023 nekuda kwehudyu.uye kurwadziwa kwechiunoPakuongororwa, ma lymph nodes akawanda akawanikwa akakura mu retroperitoneum, groin, nedzimwe nzvimbo, zvichiratidza kuti akaonekwa aine kenza yepamusoro ye serous ovarian. Saka Ms. H akaongororwa ne chemotherapy, oparesheni, immunotherapy, nezvimwewo, asi mhedzisiro yacho yakanga isina kunaka, uye bundu racho rakadzoka zvakare.
Saka, Mai H vakapinda mukuyedzwa kwekiriniki kweTIL cell therapy GC203, uye mushure memwedzi mumwe chete wekurapwa neGC203, bundu iri rakaderera ne37.3%.
Mhedziso: Kuiswa kweGC203ine kuchengetedzeka kunogamuchirika uye inoshanda zvakasimba muvarwere vane OC vanodzoka vane sarudzo shoma dzekurapa.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Mareferensi
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Nguva yekutumira: Zvita-11-2024